Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07673237 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring

Study acronym: RESPOND-ILD
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fields
  2. Recruitment opened Interventions modified · Eligibility criteria shortened, about 2 words Show 2 more changesShow less
    • Interventions modified
    • Eligibility criteria shortened, about 2 words
  3. Trial status: Not Yet Recruiting to Recruiting Start date: Aug 1, 2026 to Oct 1, 2026 · Interventions: Home Monitoring in Patients with f-ILD (Behavioral) to Oximeter (Device), Scale (Device), Spirometer (Device), ePROs (electronic patient reported outcomes) (Other) · Secondary endpoints: details revised at 5 of 9 entries · 3 more Show 6 more changesShow less
    • Start date: Aug 1, 2026 to Oct 1, 2026
    • Interventions: Home Monitoring in Patients with f-ILD (Behavioral) to Oximeter (Device), Scale (Device), Spirometer (Device), ePROs (electronic patient reported outcomes) (Other)
    • Secondary endpoints: details revised at 5 of 9 entries
    • Site details revised
    • Publications: details revised at 9 of 9 entries
    • Eligibility criteria expanded, about 4 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data completeness) and acceptable when used for the detection of clinically significant Interstitial Lung Disease events.
Trial Details
NCT Number NCT07673237
Lead Sponsor University of California, San Francisco
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), patientMpower Ltd.
Conditions Fibrotic Interstitial Lung Disease, IPF and PPF, Lung Fibrosis Interstitial
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov